Details for New Drug Application (NDA): 210137
✉ Email this page to a colleague
NDA 210137 describes FEXOFENADINE HYDROCHLORIDE ALLERGY, which is a drug marketed by Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Granules, Hetero Labs Ltd V, Rising, Sciegen Pharms Inc, Sun Pharm Inds, Teva, Unique, and Wockhardt, and is included in ten NDAs. It is available from eighty-nine suppliers. Additional details are available on the FEXOFENADINE HYDROCHLORIDE ALLERGY profile page.
The generic ingredient in FEXOFENADINE HYDROCHLORIDE ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
The generic ingredient in FEXOFENADINE HYDROCHLORIDE ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and four suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
Summary for 210137
| Tradename: | FEXOFENADINE HYDROCHLORIDE ALLERGY |
| Applicant: | Unique |
| Ingredient: | fexofenadine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 210137
| Mechanism of Action | Histamine H1 Receptor Antagonists |
Suppliers and Packaging for NDA: 210137
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FEXOFENADINE HYDROCHLORIDE ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 210137 | ANDA | Spirit Pharmaceuticals LLC | 68210-0122 | 68210-0122-1 | 100 TABLET in 1 BOTTLE (68210-0122-1) |
| FEXOFENADINE HYDROCHLORIDE ALLERGY | fexofenadine hydrochloride | TABLET;ORAL | 210137 | ANDA | Spirit Pharmaceuticals LLC | 68210-0122 | 68210-0122-3 | 1 BOTTLE in 1 CARTON (68210-0122-3) / 30 TABLET in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | OTC | Dosage: | TABLET;ORAL | Strength | 180MG | ||||
| Approval Date: | Aug 13, 2018 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
